CA 19.9

Function

Carbohydrate Antigen 19-9 (CA 19-9) is a tumor-associated antigen, specifically a sialylated Lewis blood group antigen. While it is produced in small amounts by normal cells in the biliary tract and pancreas, it is shed in significantly higher quantities by certain tumor cells. It is not used as a primary screening tool for the general population but is an invaluable biomarker for monitoring disease progression.

Why it is Ordered

CA 19-9 is most frequently ordered for patients diagnosed with pancreatic adenocarcinoma. It helps clinicians assess the effectiveness of chemotherapy, radiation, or surgical intervention. If levels drop during treatment, it generally suggests the therapy is working. It is also used to monitor for cancer recurrence after treatment has been completed. Occasionally, it may be ordered alongside other imaging to evaluate masses in the pancreas or bile ducts.

Associated Conditions

• Pancreatic Cancer: The primary use for this marker.
• Cholangiocarcinoma: Cancer of the bile ducts frequently elevates CA 19-9.
• Benign Biliary Obstruction: Gallstones or bile duct inflammation (cholangitis) can cause significant elevations.
• Cirrhosis and Hepatitis: Chronic liver diseases can result in moderate increases.
• Cystic Fibrosis: Some patients with this genetic condition show elevated levels without malignancy.